Clinical Trials
16 trialsNCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07234162 2025-11-18
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06072131 2025-10-23
CRESCENDO
Acrotech Biopharma Inc.
Phase 3 Recruiting
NCT01336933 2023-09-22
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
University of Nebraska
Phase 2 Completed
NCT01947140 2022-11-23
PDX+Romi
Columbia University
Phase 1/2 Completed
NCT01420679 2021-11-19
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02594267 2021-07-27
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT00364923 2019-12-19
PROPEL
Acrotech Biopharma Inc.
Phase 2 Completed
NCT02106650 2019-11-20
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Acrotech Biopharma Inc.
Phase 2 Completed
NCT03349333 2019-10-01
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT03355768 2018-12-19
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Columbia University
Phase 3 Withdrawn
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed
NCT03356678 2017-11-29
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
Samsung Medical Center
Completed
NCT02013362 2017-11-09
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mundipharma K.K.
Phase 1/2 Completed
NCT03150602 2017-05-12
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Unknown